The FDA is expected to announce its decision on whether or not to approve Avacincaptad pegol for the treatment of geographic atrophy secondary to age-related macular degeneration on August 19, 2023.Avacincaptad pegol, also known as Zimura, came under Astellas’ fold, following the acquisition of Iveric Bio for $5.9 billion last month. If approved, Zimura has the potential to achieve blockbuster sales across the world, according to analysts.ALPMY.OB closed Friday’s (Jul.28, 2023) trading at $14.85, down 1.33%.